Monoclonal Antibodies for Oncology Global Markets Report 2022: New Product Launches, Rising Healthcare Expenditures and Government Funding, & Licensing and Collaboration Agreements

16 Sep 2022
www.prnewswire.com
AntibodyBiosimilarAcquisitionCollaborate
DUBLIN, Sept. 16, 2022 /PRNewswire/ -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to
ResearchAndMarkets.com's offering.
The current report provides detailed exposure of global monoclonal antibodies for the oncology market.
This report highlights the current and future market potential of monoclonal antibodies for oncology treatment and includes a detailed analysis of the market's drivers, challenges, and opportunities.
The report also covers market projections to 2027 and market share for key market players. The report details the market share of monoclonal antibodies for oncology based on type and application.
The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the impact of the COVID-19 pandemic on this market.
25 data tables and 24 additional tables
A brief general outlook of the global monoclonal antibodies for oncology market
Analyses of the global market trends, with market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Highlights of the current and future market potential of monoclonal antibodies for oncology treatment, and areas of focus to forecast this market into various segments and sub-segments
Evaluation of the actual market size for monoclonal antibodies in oncology treatment, forecasted growth trends, and corresponding market share analysis by type of antibody, application area, and region
Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2022 to 2027)
In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
Review of the patent landscape and new developments in the market for monoclonal antibodies for oncology and associated clinical trials
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Key Topics Covered:
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Monoclonal Antibodies
History of Monoclonal Antibodies
Advantages and Disadvantages of Monoclonal Antibodies
Monoclonal Antibodies in Oncology
Types of Monoclonal Antibodies
Chapter 4 Market Dynamics
Market Drivers
Increasing Incidence of Cancer
New Product Launches
Rising Healthcare Expenditures and Government Funding
Licensing and Collaboration Agreements
Market Barriers
Price Controls
Regulatory Approval Pressures
Entry of Biosimilars
Opportunities
Impact of Covid-19
Chapter 5 Market Breakdown by Type
Types of Monoclonal Antibodies for Oncology
Market Overview
Market Revenue
Global Market for Monoclonal Antibodies in Oncology by Type
Humanized Monoclonal Antibodies
Human Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Chapter 6 Market Breakdown by Application
Overview
Chapter 7 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 8 Regulatory Aspects
New Approvals of Monoclonal Antibodies for Oncology
Recalls, Withdrawals, and Safety Alerts
Chapter 9 Patent Review/ New Developments
New Developments
Phase I Clinical Trials
Phase Ii Clinical Trials
Chapter 10 Competitive Landscape
Mergers, Acquisitions, and Collaborations
Company Market Shares
F. Hoffmann-La Roche AG
Merck Kgaa
Seagen
For more information about this report visit https://www.researchandmarkets.com/r/9v5j5d
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.